Enveda raises $311M Series E to advance inflammation and weight-maintenance pipeline on September 23, 2026 AI drug discovery Catalio Capital Management Dermatitis, Atopic ENV-294 ENV-308 ENV-6946 Enveda Biosciences Glucagon-Like Peptide 1 Inflammatory Bowel Diseases Lac-Phe Series E +